Ordering a lab test has gotten easier. Getting results has gotten faster. What happens between those results landing in an inbox and a person actually doing something useful with them has not kept pace, and a growing body of research suggests that gap is where a lot of the value of testing quietly disappears.
This is not a new problem in medicine. It has become a bigger one as more people order tests directly, without a clinician already attached to the process.
The Documented Problem of Results Lost to Follow-Up
Researchers have studied this question inside traditional healthcare settings for two decades, and the findings are consistent. A 2022 study on direct patient notification found that even when abnormal lab results are transmitted electronically, about 7% are never followed up on at all. A 2020 study using human factors methods to examine the issue in outpatient clinics described inadequate follow-up of abnormal test results as a recognized patient safety problem that contributes to missed and delayed diagnoses.
A 2023 systematic review focused specifically on cervical cancer screening found that inadequate follow-up of abnormal results in primary care was common enough to measurably worsen outcomes, including higher mortality. None of this research was conducted on direct-to-consumer testing. It describes what already happens inside conventional care, where a physician ordered the test, knows the patient, and still has to actively manage getting that patient back in for the next step.
That detail matters. If the existing system loses track of results even with a treating physician in the loop from the start, a process that begins with no physician involved at all does not have a smaller problem to solve. It has a different and, in some ways, more difficult one.
What Direct-to-Consumer Platforms Actually Provide After Testing
It is worth being specific about what major direct-to-consumer platforms say they do once results come back, because the answer is not nothing.
Function Health states that a clinician reviews every result and adds notes when something falls outside the expected range, and that a healthcare provider will call a member directly if a result is flagged as critical. Members also receive a written action plan and can download a PDF of their results to bring to their own doctor.
In practice, that structure still leaves a gap between notification and resolution. One reviewer who used the platform across a full year described the experience candidly: seeing abnormal results appear on the dashboard before the clinician notes arrived caused real worry, and searching unfamiliar biomarker names online sometimes led to what the reviewer called catastrophic thinking. The same reviewer noted that the lack of immediate access to a clinician who could discuss results in real time sometimes delayed action, even when the written guidance eventually arrived.
This is not a criticism unique to one company. It reflects a structural feature of any service built around periodic, asynchronous review. A clinician reading a result two or three days after a member sees the number on a dashboard is still faster than most traditional care. It is not the same as a clinician who already knew the test was being ordered, why, and what would happen depending on the outcome.
Why Professional Medical Groups Remain Cautious
STAT News reported in January 2026 that physicians are increasingly receiving self-ordered lab results from patients without the context that normally accompanies a clinician-ordered test, making it harder to know what, if anything, the result actually requires. The College of American Pathologists has acknowledged real utility in direct-to-consumer testing, including earlier detection of treatable conditions, while also noting that some tests in this category are regulated more loosely than traditional clinical lab tests and are not independently assessed for safety or efficacy before reaching consumers.
Medical groups have flagged a related concern for years: unguided testing can produce false positives or borderline results that prompt unnecessary follow-up testing, unnecessary anxiety, or both, particularly when a result arrives without anyone available to immediately put it in context. A study on automated result interpretation found a related pattern in the opposite direction. Patients who received plain-language interpretations of results directly, without a clinician present, sometimes followed up less rather than more, because the interpretation itself reduced their sense of urgency even when follow-up was still appropriate.
Put together, the research suggests two separate failure modes. Patients can ignore a result that needed attention because no one made the next step obvious. Or patients can over-interpret a result that did not need attention, because no one was available to provide proportionate context. Both outcomes trace back to the same root cause: a result without a person attached to it who already understands the patient.
Closing the Gap With a Provider Already in the Loop
Some newer platforms have tried to solve this by changing when the provider gets involved, rather than how thoroughly. Fullscript Journeys, launched broadly in April 2026 by health technology platform Fullscript, builds provider review into the testing process from the start rather than adding it after a result already exists. A patient can begin a Journey through their own provider, and that provider reviews the lab results and signs off on any resulting plan before it reaches the patient.
The distinction is timing, not just access. A provider who already has a relationship with the patient, who ordered or approved the specific test, and who is reviewing the result as part of an existing course of care is positioned differently than a clinician encountering a stranger’s data for the first time after the fact. The patient is not searching unfamiliar biomarker names alone while waiting for a note. The next step, if there is one, comes from someone who already has the context to make it specific.
This does not eliminate the broader follow-up problem the research describes. Provider attention does not automatically prevent something from falling through the cracks, and the literature on missed follow-up exists precisely because traditional care, with a provider already attached, still loses track of results often enough to matter. What it changes is the starting position. A result that already has a clinician’s attention attached to it before it is shared with the patient has fewer places to quietly disappear than a result that arrives in an app first and looks for a clinician second.
The honest answer to what happens after lab results come back is that it depends entirely on what was built to happen next, and for a large share of testing done today, that next step was never clearly designed at all.
